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Can Radiofrequency Ablation Be Used as a 
Treatment Modality for the Management of Pul-
monary Metastatic Ameloblastoma? 
Jolie Scannell, M.D., Bill Lees, M.D., and Colin Hopper, M.D. 
We report the case of a 59-year-old woman who presented with metastatic ameloblastoma involv-
ing the lungs, 20 years after resection of the primary tumor in the mandible. The lesions were 
debulked on multiple occasions with radiofrequency ablation over an eight-year period with local 
response. There were no complications related to the procedures. We suggest that radiofrequency 
ablation is a possible treatment modality for the management and control of metastatic amelo-
blastoma. 
Introduction
Ameloblastmas represent 1% of all odontogenic 
tumours. In the World Health organisation classifica-
tion of tumours, a distinction is made between amelo-
blastoma, metastasing (malignant) ameloblastoma and 
ameloblastic carcinoma [6]. Many authorities consider 
ameloblastoma to be locally invasive but not metastas-
ing [1]. Metastatic ameloblastomas are rare occurring 
in 2-5% of cases with 80% of metastases involving the 
lung [2,3]. A literature search revealed only 42 cases of 
ameloblastomas that had metastasised to lung. Metastat-
ic deposits have also been seen in cervical lymph nodes 
(15%), spine (15%) and lower incidences in liver, brain 
and kidney. The tumours tend to be slow growing [3] 
so therapy can be carried out for tumour bulk reduction 
with a reasonable expectation of prolonged survival. Sur-
gical excision of metastatic ameloblastoma is one mode 
of treatment but there is little evidence of successful 
outcome. Chemotherapeutic regimens have shown little 
or no clinical response. There are no morphological cri-
teria to predict the potential for meatstasis [7]. However 
the initial extent of the tumour and multiple recurrences 
seem to be associated with propensity to metastasise. 
There is considerable debate on the mode of spread of 
malignant ameloblastoma. Haematogenous and lym-
phatic are likely to contribute to extrapulmonary spread. 
Inhalation from the time of initial surgery has also been 
shown to be a cause for metastatis to the lung. The case 
report highlights the use of radiofrequency ablation as 
a possible treatment modality for the management and 
control of metastatic ameloblastoma.
We describe a case of a 59-year-old woman pre-
senting with metastatic ameloblastoma, 20 years after 
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Radiofrequency ablation (RFA) is a relatively new 
and minimally invasive procedure which has been used 
for the treatment of solid tumours such as hepatocel-
lular carcinoma in patients with co-morbidities or in 
cases where surgical resection was not possible. The first 
percutaneous RFA of lung lesions was reported in 2000 
by Dupuy [12]. He successfully treated three patients 
palliatively.
Percutaneous RFA is performed with insertion of 
a needle electrode through an intercostal space into 
the lesion under image guidance. CT guidance is used 
in most cases. The electrode tip has a non–insulated 
portion connected to an RF generator that generates 
medium frequency electromagnetic waves of 400 – 500 
kHz. The patient is transformed into an electrical circuit 
with adhesive grounding pads on the thighs or back. 
The mechanism of tissue heating for radiofrequency 
ablation is frictional caused by the motion generated by 
ionic current [14,15,16]. Alternating radiofrequency 
current agitates ions in the tissue surrounding the needle 
creating frictional heat, achieving a target temperature of 
about 90° C. This denatures and destroys tissue at pre-
dictable temperatures, in a relatively predictable volume 
Discussion
Case Report
A 59-year-old female was diagnosed with ameloblas-
toma of the mandible in 1980 which was treated with 
local marginal resection. The patient remained free of 
loco-regional disease for 20 years. At routine follow up 
in 2000 she presented with breathlessness and a chest 
radiograph showed bilateral lung lesions. CT guided bi-
opsy confirmed these lesions as metastatic ameloblasto-
ma. The CT showed four metastases in the left lung, the 
largest in the posterior aspect of the left lung measuring 
66mm in diameter. There were 2 metastases in the right 
lung measuring 31mm and 44mm in size.
The patient had medical co-morbidities and owing 
to the extensive multiple pulmonary metastases, surgical 
intervention was not thought to be feasible.
Initial treatment in January 2004 consisted of 
debulking the four left lung metastases with a dual 
probe cool tip radiofrequency system under GA. Treat-
ment was guided with CT scan and 90% necrosis was 
achieved. A post ablation CT scan showed all left lung 
lesions to have reduced in size. The largest lesion de-
creased in size from 66mm to 61mm. The second largest 
lesion decreased from 43mm to 28mm.
The untreated lesions in the rightlung, however had 
increased in size, from 31 to 40 mm and from 40mm to 
48mm over 6 months. Radiofrequency ablation was car-
ried out to these lesions in June 2005. A postoperative 
ablation scan showed reduction in size of both lesions 
in the right lung. One year post ablation CT scan of the 
left lung showed regrowth of the largest lesion. Radiof-
requency ablation was repeated 2 further times over a 6 
monthly period.
A CT scan in June 2006, showed focal enhancement 
in the smaller lesions, indicating residual tumour, but no 
significant progression.
Further radiofrequency ablation was carried out to 
resection of the primary tumour in the mandible. This 
represents one of the longest period between initial 
diagnosis and lung metastasis. The longest period 
between initial diagnosis and lung metastasis 29 years 
after the primary tumour was resected, was reported in 
2001 [4]. In this case report, we also highlight the use of 
radiofrequency ablation as a possible treatment modality 
for management and control of pulmonary metastatic 
ameloblastoma. 
the dominant metastasis in the left lung in December 
2006. A CT scan carried out in May 2007, revealed no 
major regrowth of the pulmonary metastases since the 
last treatment.
A CT scan October 2007 revealed good healing 
of the previously ablated areas and the overall bulk 
of the lung metastases had diminished significantly, 
although viable tumour was still present in both lungs. 
Further radiofrequency ablation was carried out to left 
lung in October 2007. A post operative scan in April 
2008 showed a good result in terms of volume of tissue 
ablated. There was still some active tumour in the largest 
lesion in the left lung and in those areas of the smaller 
lesions immediately adjacent to the heart but the bulk of 
tumour had been destroyed in the left lung. There were 
no postoperative complications such as pneumothorax 
and all radiofrequency ablation treatments were CT-
guided. Radiofrequency ablation had been well tolerated 
with minimal morbidity and was clinically effective in 
debulking the pulmonary metastatic lesions and pre-
venting progression in this case. 
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Referencesleading to tissue heating. Radio frequency ablation is 
able to induce coagulative necrosis in a limited pulmo-
nary area as large as 3-5 cm depending on the blood 
flow in the treated tissue [12]. The procedure lasts for 
a time ranging from 15 to 30 minutes according to the 
size of the tumour. When technically feasible, the abla-
tion zone should include the whole lesion and one cm of 
the surrounding lung parenchyma to eradicate all pos-
sible microinvasions. A post-operative chest x-ray is car-
ried out to exclude the occurrence of any complication 
(e.g. pneumothorax), before the patient is discharged. 
A ground glass opacity surrounding the target lesion is 
generally visible on CT scan just after RFA. Complete 
ablation is seen as a residual scar.
Malignant ameloblastoma is a different clinical con-
dition from other metastatic pulmonary cancers in that 
debulking can be of clinical benefit. In the case report 
shrinkage of lesions by 12mm was achievable and there-
fore RFA could be a mode for control of pulmonary 
metastases. It is not without complications with a 40% 
incidence of pneumothorax [14,15,17,18] of which 
50% require drainage. There is a long interval between 
diagnosis and metastasis of ameloblastomas and the rate 
of metastasis is only 1-3%, it is difficult to know wheth-
er routine evaluation should be carried out to diagnose 
metastasis. Goldenberg et al recommended that all 
patients with ameloblastomas should have annual chest 
xrays as lung is the most frequent site for metastases [8]. 
Annual evaluation of the neck with ultrasound should 
also be considered for possible regional recurrences.
Lung RFA is a minimally invasive, relatively safe, 
and promising treatment for unresectable metastases 
[13]. Clinical studies have shown it to be an effective 
and reproducible method for tumour ablation [13]. 
Tumor size is an important factor in achieving complete 
tumor necrosis [9]. The case report highlights the use of 
radiofrequency ablation as a possible treatment modality 
for the management and control of metastatic amelo-
blastoma. Clinical trials are required to evaluate RFA 
as an effective treatment for pulmonary metastases in 
patients where surgical resection may not be an option. 
RCR Radiology Case Reports | radiology.casereports.net 4 DOI: 10.2484/rcr.2009.v4i2.249
Can Radiofrequency Ablation Be Used for Management of Pulmonary Metastatic Ameloblastoma? 
11. Dupuy D, DiPetrillo T, Gandhi S, et al. Radio-fre-
quency ablation followed by conventional radiotherapy 
for medically inoperable Stage I non-small cell lung 
cancer. Chest. 2006;129:738-45. [PubMed]
12. Goldberg S, Hahn P, Tanabe K, et al. Percutaneous 
radiofrequency tissue ablation: does perfusion-mediated 
tissue cooling limit coagulation necrosis? J Vasc Interv 
Radiol 1998;9:101-11. [PubMed]
13. Kocijančič K, Kocijančič I. Radiofrequency ablation 
of lung tumours--new perspective in treatment of lung 
neoplasms. Radiol Oncol 2007;41(1): 33-8. 
14. Schaefer O, Lohrmann C, Langer M. CT-guided 
radiofrequency ablation of a bronchogenic carcinoma. 
Br J Radiol 2003;76: 268-70. [PubMed]
15. Steinke K, Habicht JM, Thomsen S, et al. CT-
guided radiofrequency ablation of a pulmonary metas-
tasis followed by surgical resection. Cardiovasc Intervent 
Radiol 2002;25:543-6. [PubMed]
16. Herrera L, Fernando H, Perry Y, Gooding W, et 
al. Radiofrequency ablation of pulmonary malignant 
tumors in nonsurgical candidates. J Thorac Cardiovasc 
Surg 2003;125:929-37. [PubMed]
17. Lencioni R, Crocetti L, Cioni R, et al. Radiofre-
quency of lung malignancies: where do we stand? Car-
diovasc Intervent Radiol 2004;27:581-90. [PubMed]
18. Lee J, Jin G, Goldberg S, et al. Percutaneous radio-
frequency ablation for inoperable non-small cell lung 
cancer and metastases: preliminary report. Radiology 
2004;230:125-34. [PubMed]
